DNP63a, the predominant TP63 isoform expressed in diverse epithelial tissues, including the mammary gland, is required for the preservation of stem cells and has been implicated in tumorigenesis and metastasis. Despite data characterizing DNP63a as a master regulator of stem cell activity, identification of the targets underlying these effects is incompletely understood. Recently, DNP63a was identified as a key regulator in the promotion of proinflammatory programs in squamous cell carcinoma of the head and neck. Inflammation has been implicated as a potent driver of cancer stem cell phenotypes and metastasis. In this study, we sought to identify novel targets of DNP63a that confer cancer stem cell and prometastatic properties. Data presented here identify the gene encoding the chemokine receptor 4 (CXCR4) as a transcriptional target of DNP63a. Our data indicate that DNP63a enhances CXCR4 expression in breast cancer cells via its binding at two regions within the CXCR4 promoter. The CXCR4 antagonist AMD3100 was used to demonstrate that the pro-stem cell activity of DNP63a is mediated through its regulation of CXCR4. Importantly, we show that DNP63a promotes the chemotaxis of breast cancer cells towards the CXCR4 ligand SDF1a, a process implicated in the trafficking of breast cancer cells to sites of metastasis. This study highlights CXCR4 as a previously unidentified target of DNP63a, which plays a significant role in mediating DNP63a-dependent stem cell activity and chemotaxis toward SDF1a. Our findings suggest that DNP63a regulation of CXCR4 may have strong implications in the regulation of cancer stem cells and metastasis.
Introduction
TP63, a member of the P53 family of transcription factors encodes multiple isoforms via a combination of differential promoter usage and alternative C-terminal splicing. TAp63 isoforms contain full-length N-terminal transactivating domains while DNp63 isoforms have a truncated N-terminus (1) . DNp63a is the most abundant isoform expressed in the majority of epithelial tissues including the mammary epithelium (2) . Substantial evidence implicates DNp63a in the maintenance of epithelial stasis, particularly through the preservation of selfrenewing capacity (3, 4) . Recently, we have defined a regulatory pathway by which miR203-dependent suppression of DNP63a promotes forfeiture of self-renewing capacity in a mammary stem cell model programmed to undergo luminal differentiation (5) . In the context of cancer, DNP63a has been identified as an oncogene, where it was found to drive epidermal stem cell proliferation and tumorigenesis (6) . Likewise, in human breast tumors, DNp63a expression is highly enriched in the breast cancer stem cell population (7) . Interestingly, a recent study determined that collective invasion in breast cancer, a process by which tumors invade surrounding normal tissue as a multicellular unit is mediated by carcinoma cells expressing basal epithelial markers including DNp63a and that suppression of DNp63a was sufficient to block collective invasion (8) . These findings coupled to studies identifying DNp63a as a prosurvival factor and mediator of chemoresistance in basal breast cancers and head and neck squamous cell carcinomas (HNSCC; refs. 9, 10) highlight its role in epithelial tumor initiation, progression, and metastasis.
Accumulating evidence indicates that a subpopulation of cancer cells with stem cell properties play a crucial role in tumorigenesis, metastatic development, and resistance to therapy. These cancer stem cells (CSC), like normal stem cells, retain self-renewing capacity and their mitotic offspring differentiate into the various cell populations within the tumor mass (11) (12) (13) . Recently, we reported that DNp63a expression is significantly enriched in self-renewing populations of normal murine and malignant human mammary stem cells, respectively (5, 14) . In addition to its role in tissue and tumor stasis, DNp63a regulates proinflammatory gene expression and a malignant phenotype in HNSCC (15) by forming novel complexes with NF-kB family members. NF-kB signaling is required for CSC activity in multiple cancers including basal breast cancer (16, 17, 18) . In addition, DNp63 isoforms have been identified as a marker of the basal breast cancer subtype (19) , where it functions to regulate cancer cell survival and drug resistance (9) . Together, these studies suggest that DNp63a directs expression of proinflammatory genes via interactions with NF-kB and that this class of target genes plays a role in tumor progression and metastasis.
Accumulating evidence highlights the role of inflammation and cytokine networks in the cancer initiation and progression and more recently, in the regulation of CSC populations (20, 21) . Many of the cytokines present in the tumor microenvironment and premetastatic niches bind to receptors present on cancer stem cells, which subsequently converge on several pathways including Notch, PI3K/AKT, Wnt, NF-kB, and Jak/Stat to activate self-renewal and prosurvival pathways (21) (22) (23) . Despite DNp63a's role in the preservation of stem cell renewal, the target genes and mechanisms by which DNp63a mediate such phenotypes are incompletely defined. Based upon the ability of DNp63a to coregulate NF-kB target genes, we sought to identify targets of DNp63a implicated in inflammation and CSC activity to gain a better understanding of the mechanisms by which DNp63a functions. Here, we report that the gene encoding the chemokine receptor 4 (CXCR4) is a transcriptional target of DNP63a. CXCR4 belongs to a class of receptors that bind the conserved CXC class of chemokines, which have a single nonconserved amino acid residue (X) between the first N-terminal cysteine residues (C; ref. 24) . CXCR4 is a G-protein-coupled receptor, that, when activated by its only known ligand, CXCL12 (stromal derived factor-1; ref. 25) , initiates the activation of diverse downstream signaling pathways including MAPK, PI3K, AKT, JAK/STAT, and NF-kB to promote cell survival, proliferation, and migration (25) (26) (27) . Under normal physiologic conditions, the CXCL12-CXCR4 network plays a vital role in the regulation of normal stem/progenitor and hematopoietic cell trafficking and homing (28, 29) . However, in solid tumors, CXCR4 has been shown to be markedly overexpressed relative to matched normal tissues. In the breast, CXCR4 regulates the chemotaxis of breast cancer cells to sites of metastasis in which high levels of SDF-1a (CXCL12) have been observed (30) . In addition, CXCR4 plays a central role in metastasis and has been implicated in self-renewal and survival of CSCs (31, 32) . Here, we demonstrate that DNP63a binds to conserved p63-binding motifs within the CXCR4 promoter and positively regulates CXCR4 gene expression. We demonstrate that DNP63a-mediated expression of CXCR4 influences stem cell activity and chemotaxis in response to SDF1a. Together, this study identifies a novel and significant transcriptional target of DNP63a and brings to light the possible function of DNP63a in breast CSCs to mediate metastasis.
Materials and Methods

Cell culture
The human breast cancer cell lines MCF7, MDA-MB-231, and the lung cancer cell line H1299 were obtained from the ATCC and grown in DMEM supplemented with 10% FBS and 0.2 IU/mL insulin for MCF7 cells. Derivation and maintenance of the immortalized mammary epithelial cell (IMEC) line has been previously described (5) . The human breast cancer cell line SUM-102 was grown in Ham/F-12 medium supplemented with 1 mmol/L HEPES, 2% FBS, 5 mg/mL insulin, 1 mg/mL hydrocortisone, 10 ng/mL EGF and penicillin/streptomycin. No cell line authentication was done by the authors.
Plasmid and viral constructs and transfection and infection assays
For experiments involving stable overexpression of DNP63a, IMECs were transfected with an empty control mammalian expression plasmid (pCDNA-Ctr) or one encoding human DNP63a (pCDNA-DNP63a) using Lipofectamine 2000 Transfection reagent (Invitrogen). Both expression plasmids were linearized via restriction enzyme digestion. Twenty-four hours after transfection, cells were selected under G418 (2 mg/mL) to establish a stable cell line overexpressing DNP63a. 
Western blot analysis
Total cell protein lysates were obtained using NETN lysis buffer [100 mmol/L Tris-Cl (pH 7.8), 1 mmol/L EDTA, 100 mmol/L NaCl, and 0.1%Triton X-100)] supplemented with protease and phosphatase inhibitors (Roche). Protein lysate concentration was measured by Lowry protein assay and 10 mg of protein per well was resolved on a 10% SDS-polyacrylamide gel and transferred onto a polyvinylidenedifluoride membrane. Membranes were subsequently blocked in TBST 5% dry milk for 1 hour at room temperature, incubated with primary antibody overnight at 4 C, washed with TBST, and incubated at room temperature for 1 hour with horseradish peroxidase-conjugated secondary antibody, and developed using enhanced chemiluminescence substrate (ECL).
Immunofluorescence
Cells were seeded onto glass chamber slides at 8,000 cells per well. Cells were then fixed using CytoRich-Red 24 hours after seeding. Slides were washed three times (PBS/0.1% Tween-20) and blocked for 2 hours in 5% goat serum/0.5% Tween-20/PBS at room temperature. Samples were incubated with anti-CXCR4 primary antibody (8 mg/mL) diluted in blocking buffer for 45 minutes at 37 C, washed once, and subsequently incubated with anti-mouse Alexa Fluor 488 secondary antibody for 15 minutes at 37 C. Glass slides were mounted in Vectashield with 4 0 ,6-diamino-2-phenylindole (DAPI; Vector Laboratories) and imaged via fluorescence microscopy. To control for nonspecific fluorescence, a set of cells were stained with secondary antibody only. All fluorescent and phase contrast images were visualized and captured using a Nikon Eclipse TS100 inverted microscope coupled to a RT Slider Spot charge-coupled device camera. Quantification of fluorescent intensity was performed using ImageJ software.
Antibodies
For Western blotting, mouse anti-p63 (4A4; LabVision; 1/1,000 dilution), mouse anti-b-actin (1/1,000 dilution), rabbit anti-SDF1 (1/1,500 dilution) (Cell Signaling Technology), and rabbit anti-CXCR4 (1/500; Abcam) antibodies were used. For immunofluorescence experiments, rabbit anti-CXCR4 (1/500; Abcam; Fig. 1C ) or mouse anti-CXCR4 (R&D Systems; 8 mg/mL dilution; Supplementary Fig. S2B ) antibodies were used. Secondary antibodies used were anti-mouse and anti-rat IgG horseradish peroxidase-conjugated for immunoblot and goat anti-rabbitAlexaFluor-555 or goat anti-mouse-AlexaFluor-488-conjugated antibodies for immunofluorescence. 
Luciferase reporter assay
Oligonucleotides representing the two putative p63-binding elements identified in the CXCR4 promoter were concatenated and ligated unidirectionally upstream of the minimal promoter of the HSV16 thymidine kinase promoter and firefly luciferase (ptk-Luc). Resulting reporters including parental tk-Luc were transfected into H1299 cells along with expression vectors encoding Renilla luciferase and either an empty vector or DNp63a. Twenty-four hours after transfection, cells were harvested and analyzed for luciferase activity using the DualLuciferase Reporter Assay System (Promega) as per manufacturers' protocol.
Colony formation analysis
IMECs stably overexpressing DNP63a or empty control vector (IMEC-pCDNA-DNP63a or IMEC-pCDNA) were plated at colony formation density (6,000 cells per 10 cm tissue culture plate) and treated in the presence of vehicle control (H 2 O) or the CXCR4 antagonist AMD3100 (5 mmol/L). Colonies were stained using crystal violet 14 days after plating.
Mammosphere formation assay
The human breast cancer cell line, MCF7, was infected with retrovirus to stably overexpress DNP63a or empty control (MCF7-pLPC-DNP63a and MCF7-pLPC) and seeded (5,000 cells per plate) onto 10 cm ultra-low attachment surface tissue culture plates (Corning Inc.). Cells were treated in the presence of vehicle control (H 2 O) or the CXCR4 antagonist AMD3100 (5 mmol/L). Cells were grown in low binding conditions for 6 days and later quantified.
qRT-PCR analysis
RNA was isolated using the RNeasy Kit (Qiagen) as per manufacturer's protocol. RNA (1 mg) was reverse transcribed into cDNA using the iScript cDNA Synthesis Kit (Bio-Rad). Quantitative PCR was carried out using the iQ SYBR Green Super Mix (Bio-Rad) and oligonucleotide primers specific to each target gene. The 2
ÀDDCt method was used for quantification of relative gene expression changes and normalized to GAPDH.
Chromatin immunoprecipitation assay
Cross-linking was performed by treating cells with media supplemented with 1% formaldehyde for 10 minutes at 37 C. Cells were washed once in PBS/BSA (5 mg/mL) and then lysed at room temperature in lysis buffer (1% SDS, 10 mmol/L EDTA, 50 mmol/L Tris-HCl pH 8.1, and protease inhibitor). DNA fragmentation was performed using a bioruptor. Lysates were subjected to 3 Â 5 minute sonication periods at 30 second on/off cycles. Lysates were then spun down and aliquots of the supernatant were taken for input control. Supernatants were then diluted 1:10 in dilution buffer (1% Triton, 2 mmol/L EDTA, 150 mmol/L NaCl, 20 mmol/L Tris-HCl pH 8.1) which were subsequently added to a 1:1 mixture of A and G Dynal beads complexed with either IgG isotype control or anti-p63 (4A4) antibodies (2.5 mg) and immunoprecipitated overnight on a rotator at 4 C. The immunoprecipitation complex was washed 4 Â 5 minutes in cold RIPA buffer (50 mmol/L HEPES pH 7.6, 1 mmol/L EDTA, 0.7% Na Deoxycholate, 1% NP-40, 0.5 mol/L LiCl) followed by washing twice in cold Tris-EDTA Buffer (TE; pH 7.6) buffer. The immunoprecipitation complex was then reverse cross-linked in a 0.1 mol/L NaHCO 3 solution containing 1% SDS at 65 C overnight. DNA was isolated using the QIAgen PCR purification kit. Isolated DNA was analyzed using qRT-PCR.
Predicted p63-binding sites and designed PCR primers used in ChIP assay
Putative p63-binding sites on the CXCR4 gene promoter were predicted on the basis of the p63 canonical binding motif (RRRCWWGYY). The top scored putative p63-binding sites (6 or greater complementary nucleotides per p63-binding site with minimal nucleotides between p63 dimers) were selected in the range of À2,000 bp to þ2,000 bp from the transcription starting site (TSS) of the CXCR4 promoter. Chromatin immunoprecipitation (ChIP) experiments identified significant p63-binding activity over IgG isotype controls at 2 CXCR4 promoter sites, and a known p63-binding site in the CSF2 gene. The sequences of the designed primers for these binding sites are as follows: CXCR4, p63-binding site (À547 bp): forward primer: 
Chemotaxis assay
For chemotaxis assays, 4 Â 10 5 MCF10A-Ctrl or MCF10A-pBABE-SDF1a cells were seeded in the bottom well of a Boyden chamber two days before the addition of polycarbonate membrane (8 mm pore size). A total of 2 Â 10 5 SUM102 cells that were infected with either an empty adenoviral control, or one containing the open reading frame of DNP63a was seeded in the top chamber 24 hours after infection. After 20 hours of incubation at 37 C, the cells were fixed in 4% paraformaldehyde for 20 minutes, and the nonmigrated cells on the top of the membrane were removed. The migrated cells on the bottom of the chamber were stained in crystal violet and placed on glass slides. The number of stained cells was counted under a microscope at 10 different fields.
Results
DNP63a positively regulates the expression of CXCR4 mRNA DNp63a interacts with NF-kB and contributes to the regulation of proinflammatory NF-kB-driven transcriptional networks and distinct cytokines which contribute to the governance of stem and CSC activity. This suggests that DNP63a-mediated preservation of stem cell phenotype is carried out through the transcriptional regulation of inflammation-associated genes. We therefore analyzed the relative change in mRNA expression of several well-characterized genes associated with inflammation in response to overexpression of DNP63a and found CXCR4 expression to be significantly induced in SUM102 cells which were selected for their intermediate level of DNP63a protein expression (Fig. 1A, left: protein expression, right: mRNA expression, Supplementary Fig. S1 -validated targets of DNP63a as control, Supplementary Fig. S2A -endogenous DNP63a protein expression in mammary and breast cancer cell lines). CXCR4 was similarly induced upon DNP63a overexpression in IMEC, and the breast cancer cell lines MCF7 and MDA-MB-231 (Supplementary Fig. S2B ). In addition, immunofluorescent imaging of SUM-102 cells overexpressing DNP63a revealed a substantial induction in CXCR4 protein expression compared with adenoviral control (Supplementary Fig. S2C ). Consistent with these results, siRNA-mediated depletion of DNP63a from SUM-102 cells (Fig. 1B, left) ; decreased the expression of CXCR4 mRNA (Fig. 1B, right) , which was also observed in IMECs (Supplementary Fig. S2D ). In addition, immunofluorescent imaging of normal IMECs and the breast cancer cell line SUM-102 revealed that both DNP63a and CXCR4 protein are coexpressed within the same cell (Fig. 1C) . Remarkably, transfection of miR203, which targets DNP63a in mammary epithelial cells (5), also repressed CXCR4 mRNA expression ( Supplementary Fig. S3 ), further implicating DNP63a in the positive regulation of CXCR4. Taken together, these results indicate that DNP63a positively regulates the expression of CXCR4.
DNP63a binds to the CXCR4 promoter region
The ability of DNP63a to positively regulate the expression of CXCR4 mRNA (Fig. 1) suggests that it may bind to its promoter region to facilitate transcription. To address this, we searched the CXCR4 promoter for consensus p63-binding elements and identified two putative p63-dimer-binding sites ( Fig. 2A and Materials and Methods). Anti-p63 ChIP leads to a sharp enrichment of genomic fragments containing these sequences in SUM-102 cells ( Fig. 2A and B) and in hTERT IMEC (Supplementary Fig. S4A ). Consistent with this observation, ectopic expression of DNp63a enhanced binding of these genomic regions ( Supplementary Fig. S4B ). Under identical conditions, a known p63-binding element in the CSF2 promoter was enriched by p63-directed ChIP as a positive control and random genomic regions within the CXCR4 promoter was used as a negative control ( Fig. 2A and B and Supplementary Fig. S4C , respectively; ref. 15) . To determine the functional significance of the observed p63 binding within the CXCR4 promoter, the identified elements were subcloned upstream of a heterologous promoter and firefly luciferase (Fig. 2C) . Compared with parental luciferase control constructs (tk-luc), reporter constructs containing either of the two p63-binding sites displayed significantly greater luciferase intensity in the presence of ectopic DNP63a (Fig. 2C ). Taken together, these studies demonstrate that DNP63a binds to two predicted binding sites on the CXCR4 promoter and positively regulates the transcription and subsequent protein expression of CXCR4.
DNP63a-dependent regulation of stem cell activity is mediated through induction of CXCR4 expression
The ability of DNP63a to positively regulate expression of CXCR4 suggests that CXCR4 may mediate some of the activities ascribed to DNP63a. Several studies have begun to illuminate the influence of various cytokines over stem cell regulation and phenotype (21) . CXCR4 has been implicated in normal stem cell and cancer stem cell function as well as cancer progression and metastasis (31, 32) . This, combined with abundant evidence implicating DNP63a in the maintenance of self-renewing capabilities in stem cells suggest that this role of DNP63a may be mediated through its regulation of CXCR4 (3, 5) . To test this, clonogenicity assays were performed on IMECs infected with control or an adenovirus programmed to express DNP63a, and then treated in the presence or absence of a small-molecule inhibitor against CXCR4 (AMD3100). Results revealed that ectopic DNP63a significantly enhanced clonogenic capacity of IMECs and this was sensitive to CXCR4 inhibition with AMD3100 (Fig. 3A) . Consistent with this result, ectopic expression of DNP63a in MCF7 cells induced expression of CXCR4 ( Fig. 3B and C) and sharply increased mammosphere-forming capacity in a manner that was sensitive to AMD3100 (Fig. 3D) . Importantly, the ability of AMD3100 to oppose mammosphere formation required ectopic DNP63a (Fig. 3D and Supplementary Fig. S5 -the ligand to CXCR4, SDF1a is present at detectable levels in the cell culture media used in the above experiments). Taken together, these studies indicate that the ability of DNP63a to enhance breast cancer stem cell activity is mediated through its positive regulation of CXCR4 and its subsequent downstream activity.
DNP63a mediates sensitivity to CXCR4 inhibition
Stem cells and CSCs have been shown to possess enhanced prosurvival signaling and rely heavily on, in part, AKT and JAK/ STAT pathways, both of which have been demonstrated to be activated by CXCR4 signaling (25) . In addition, several studies highlight the prosurvival, antiapoptotic activity of DNP63a, especially in the context of chemoresistance and tumorigenesis (9, 10, 34) . These studies coupled with data indicating that DNP63a-mediated breast CSC activity involves expression and activity of CXCR4 suggests that DNP63a expression may confer sensitivity to CXCR4 inhibition. To determine this, we utilized the highly aggressive breast cancer cell line MDA-MB-231, which lacks endogenous expression of DNP63a (Supplementary Fig. S2A) , and infected them with either an empty adenovirus as a control or an adenovirus programmed to express DNP63a. Cells were re-fed every other day in the presence or absence of the CXCR4 inhibitor AMD3100 (5 mmol/L) for 7 days. Crystal violet staining of the cells after 7 days of treatment revealed minimal to no loss in cell density (Fig. 4A ) or cell number (Fig. 4B) between control MDA-MB-231 cells (Adv-Ctrl) treated in the presence or absence of AMD3100. However, ectopic DNP63a sensitized MDA-MB-231 cells to the CXCR4 inhibitor AMD3100 (Fig. 4) , suggesting that DNP63a-dependent regulation of CXCR4 is critical for cellular viability. This is further supported by Trypan blue exclusion viability Research.
on October 13, 2017. © 2014 American Association for Cancer mct.aacrjournals.org Downloaded from experiments of MDA-MB-231 cells expressing an adenoviral empty control or one expressing DNP63a treated in the presence or absence of the CXCR4 inhibitor AMD3100 (Fig. 4C) . Results demonstrate that MDA-MB-231 cells overexpressing DNP63a exhibit significant reductions in cell viability in the presence of AMD3100 compared with controls (Fig. 4C) . Taken together, with previous studies demonstrating the prosurvival effects of both DNP63a and CXCR4, the above data suggest that DNP63a regulates cellular viability in part, through its regulation of CXCR4 and also suggests that DNP63a may act as a marker for CXCR4 inhibition or anti-CXCR4 therapies.
DNP63a positively regulates sdf1a-dependent chemotaxis of breast cancer cells
Under normal physiologic conditions, SDF1a (CXCL12) acts as a chemoattractant for immature and mature hematopoietic cells, for which the cognate receptor CXCR4 is expressed at its highest levels, thus playing a vital role in immune surveillance at distant tissues and inflammatory processes (25) . More recently, it has been established that CXCR4 expression is significantly increased in various cancers, including breast cancers compared with their normal counterparts and may mediate the trafficking and invasion of these cells to distant sites of metastasis, where SDF1a is expressed. Interestingly, multiple studies have demonstrated CXCR4 as a major mediator in the development of metastasis in as many as 75% of all cancers including the breast (35) . On the basis of the demonstration that DNP63a is a positive regulator of CXCR4, which contributes to the ability of DNP63a to maintain a breast CSC phenotype, we sought to determine whether DNP63a can regulate the chemotaxis of breast cancer cells toward the CXCR4 ligand SDF1a. To do this, we performed chemotaxis assays in which we seeded the bottom layer with MCF10A cells infected with an empty retrovirus, or one encoding SDF1a, to act as the Research.
on October 13, 2017. © 2014 American Association for Cancer mct.aacrjournals.org Downloaded from source of the chemoattractant (SDF1a). This was then followed by seeding the top membrane with control SUM-102 cells or SUM-102 cells overexpressing DNP63a (Fig. 5A) . Under these conditions, only SUM-102 cells overexpressing DNP63a displayed significant migratory activity in the presence of SDF1a. Moreover, this DNp63a-mediated migration appears to be dependent on SDF1a/CXCR4 signaling, as there was no significant induction of migration in the absence of the chemokine or DNP63a (Fig. 5B and C) . Taken together, this result demonstrates the ability of DNP63a to promote (>2-fold) the migratory activity of breast cancer cells via its modulation of CXCR4 and may therefore play a significant role in the development of breast cancer metastasis.
Discussion
The majority of cancer mortality is the result of advanced metastatic disease (36) . CSCs have been shown to be capable of migrating to metastatic sites and eventually differentiate into diverse cell types that make up the tumor bulk (37) . Here, we report a novel regulatory relationship between the CSC prosurvival factor, DNP63a, and the prometastatic gene CXCR4. We demonstrate not only that CXCR4 mediates the pro-stem cell activities of DNP63a, but also that DNP63a promotes migration of breast cancer cells in a manner that is dependent upon CXCL12-CXCR4 signaling. These findings contribute to the accumulating evidence implicating DNP63a in CSC activity and metastasis. Epithelial-to-mesenchymal transition (EMT) has also been attributed to mediating the acquisition of a CSC and a proinvasive and metastatic phenotype (38) . In addition, recent studies have implicated DNP63a in the modulation of EMT-MET transitions (39, 40) . In one study in prostate cancer, p63 was shown to inhibit EMT marker expression and lung metastasis in mouse tail vein injection models via the regulation of the miRNA miR-205 in a p53-dependent context (41) . However, in our studies, DNP63a-mediated induction of CXCR4 expression and function occurred without any changes in the protein expression of hallmark markers of EMT ( Supplementary Fig. S6 ), suggesting that the observed findings in this study are independent of DNP63a's regulation of EMT. Given this paradox by which p63 has been demonstrated to be capable of promoting or repressing EMT, it suggests that it may function as a regulator of EMT-MET plasticity. Under certain distinct contexts, p63 may be able to drive populations toward one state or the other. Further studies are needed to elucidate whether p63 can mediate such plasticity and under what contexts it drives one state over the other. CXCR4 was first shown to mediate metastasis of breast cancer towards organs expressing its ligand CXCL12 and has since been implicated in the metastatic development of up to 75% of other solid tumors (25, 35) . Not surprisingly, increased expression of CXCR4 in breast cancer has been found to be associated with poor overall survival, particularly due the development of metastatic disease (42) . The current report demonstrates that DNP63a positively regulates expression of this vital prometastatic gene. This highlights the potential significance of DNP63a as a mediator of metastasis and as a potential prognostic marker of breast cancer. Additional research is necessary to identify and characterize all mechanisms by which DNP63a contributes to disease progression, and to what extent it is due to its regulation of CXCR4. For example, it has been demonstrated that NF-kB signaling promotes breast cancer migration and metastasis via CXCR4 (43) . In addition, DNP63a and NF-kB have been shown to coregulate an overlapping subset of target genes that promote inflammation and disease progression in HNSCC (15) . In addition to CXCR4, DNP63a can also positively regulate IL6, IL8, and CSF2 (Supplementary Fig. S1 ), all of which can promote proinflammatory cellular responses linked to tumor progression, angiogenesis, invasion, and metastasis (30) . Taken together, these studies, coupled to the data presented here, illustrate the profound and potentially global influence DNP63a may have on breast cancer tumorigenesis and progression.
In glioblastoma stem cells, inhibition of CXCL12-CXCR4 signaling significantly reduced viability and self-renewing activity (31) . Here, we identified CXCR4 as a functional mediator of the observed gains in stem cell activity in response to DNP63a expression. DNP63a-dependent enhancement of clonogenicity and mammosphere-forming capacity are diminished by the CXCR4 inhibitor, AMD3100. CXCR4 0 s role in maintaining stem cells has been reported to be via multiple pathways known to be involved in stem cell renewal, suggesting that DNP63a may influence these pathways via CXCR4. This highlights the complexity of DNP63a activity and the need to elucidate the particular contexts and networks governed. In addition, data presented here implicate CXCR4 as a mediator of DNP63a-dependent viability and demonstrate that DNp63a expression predicts a response to AMD3100. An important feature of CSCs is resistance to chemotherapy (44) . Recently, CXCR4 was implicated in stem cell activity in drug-resistant NSCLC cells (32) . Likewise, DNP63a is a critical mediator of chemoresistance in HNSCC and breast cancer. These functions may overlap with and future studies should be aimed at identifying this. CXCL12-CXCR4 signaling plays an important role in the establishment of metastasis by regulating the migration of cancer cells to distant metastatic sites and by mediating the survival and proliferation of cells at these locations (25) . In a recent study from the Massague laboratory, investigators revealed that a subset of triple-negative breast tumors with high Src activity is primed for metastasis to the bone via CXCL12 signaling (45) . Given that DNP63a has been shown to activate the same downstream pathways as Src (46) combined with the data presented here identifying DNP63a as a positive regulator of CXCR4, it suggests that it may also play a role in the metastatic priming of breast cancer cells to the bone. Multiple preclinical studies have demonstrated that disruption of this pathway, either through inactivation of CXCL12 or CXCR4 drastically reduced the ability of breast cancer to metastasize to distant organs, specifically the most common sites of breast cancer metastasis, the bone and lungs (47, 48) . However, to our knowledge, there has not been a clinical trial using inhibitors of this pathway in breast cancer. Here, we demonstrate that DNP63a can mediate the migration of breast cancer cells towards CXCL12, which is highly expressed in bone and lung, the most common sites of breast cancer metastasis. Again, this stresses the potential significance of DNP63a in mediating breast cancer metastasis. In addition, DNP63a has been reported to regulate an adhesion program including b4 integrins, which have been implicated in the docking and survival of cancer cells at a distant tissue, thus promoting metastasis (49, 50) . Given this knowledge, coupled to the findings we present here in which we demonstrate that DNP63a can mediate chemotaxis, it suggests that DNP63a may denote or identify cells of particularly high metastatic potential. Further research should aim at this goal, particularly with regards to the newly identified regulation DNP63a exerts over CXCR4 presented here.
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